



Contact: Rehab AlJamal-Naylor
Tel. 017919-621 733
Email: r.aljamal.naylor@avipero.com

FOR IMMEDIATE PRESS RELEASE

Friday, 18 May 2013.

John Blenkinsopp appointed as Chief Medical Officer of AVIPERO.

EDINBURGH, SCOTLAND-Fri, 18 October, 2013-----The board of AVIPERO (Registered in Scotland SC353945) announced today Dr. John Blenkinsopp has been appointed as Chief Medical Officer. John studied Pharmacy at Bradford University and Medicine at Birmingham University. He has postgraduate qualifications in both management and Pharmaceutical Medicine. John has worked in all phases of drug development. He was a Clinical Research Physician at Hazleton Medical Research Unit (now Covance), Leeds, UK, a Phase 1 clinical research unit with 50 beds and over 40 studies completed each year. He has also worked for AstraZeneca, GlaxoSmithKline and Schering Plough.

The Director and interim CEO of AVIPERO, Prof. Robert J. Naylor, said: “John brings a wealth of experience in clinical drug development to AVIPERO with strong track record in the pharmaceutical industry. The combination of clinical and pharmacy qualifications of John makes his role in early drug development of a first-in-man disease-modifying therapeutic such as that of AVIPERO’s ideal”.

About AVIPERO Ltd.

AVIPERO Ltd (Registered in Scotland SC353945) is a private biopharmaceutical company established in 2009. Avipero is focused on the development of novel therapeutics for unmet clinical needs, characterised by a loss of cells and tissues. This includes conditions such as Parkinson’s disease (PD), chronic obstructive pulmonary disease (COPD), arthritis and age related cell decline. AVIPERO has a proprietary first-in-class therapeutic platform covered by a strong intellectual property portfolio.

Forward Looking Statements

Statements contained herein, other than those which are strictly statements of historical fact may include forward-looking information. Such statements will typically contain words such as “believes”, “may”, “plans”, “will”, “estimate”, “continue”, “anticipates”, “intends”, “expects”, and similar expressions. While forward-looking statements represent management’s outlook based on assumptions that management believes are reasonable, forward-looking statements by their nature are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by them. Such factors include, among others, the inherent uncertainty involved in scientific research and drug development, AVIPERO’s early stage of development, lack of product revenues, its additional capital requirements, the risks associated with successful completion of clinical trials and the long lead-times and high costs associated with obtaining regulatory approval to market any product which AVIPERO may develop. Other risk factors include the limited protections afforded by intellectual property rights, rapid technology and product obsolescence in a highly competitive environment and AVIPERO’s dependence on collaborative partners and contract research organizations. These factors should be considered carefully. Readers are cautioned not to place undue reliance on such forward-looking statements. Similarly, nothing in this press release is meant to promote a pharmaceutical product or make a regulated claim of efficacy.

FOR FURTHER INFORMATION PLEASE CONTACT:

Dr. Rehab AlJamal-Naylor
AVIPERO Ltd
CSO/Director,
07919-621-733
info@avipero.com
www.avipero.com